Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Arthur Kirsch sold 5,000 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $56.00, for a total value of $280,000.00. Following the completion of the sale, the director owned 10,000 shares of the company’s stock, valued at $560,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Liquidia Price Performance
NASDAQ LQDA opened at $62.32 on Friday. The company has a 50 day simple moving average of $46.27 and a 200-day simple moving average of $39.40. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of 445.20 and a beta of 0.58. Liquidia Corporation has a 52-week low of $11.85 and a 52-week high of $66.24.
Liquidia (NASDAQ:LQDA – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Equities research analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Liquidia
Hedge Funds Weigh In On Liquidia
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caprock Group LLC acquired a new position in Liquidia during the third quarter valued at approximately $37,114,000. Apis Capital Advisors LLC acquired a new position in Liquidia during the third quarter valued at approximately $9,569,000. Farallon Capital Management LLC grew its stake in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after acquiring an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Liquidia by 63.6% in the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after acquiring an additional 24,555 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Liquidia in the third quarter worth $1,536,000. Institutional investors and hedge funds own 64.54% of the company’s stock.
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Stories
- Five stocks we like better than Liquidia
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
